News Summary: Elan, Biogen revise Tysabri deal

Published on NewsOK Modified: February 6, 2013 at 5:08 pm •  Published: February 6, 2013
Advertisement
;

TAKING OVER: Biogen Idec will take over full ownership of the multiple sclerosis treatment Tysabri from its partner Elan Corp. PLC in exchange for a $3.25 billion cash payment and royalties on future sales.

CAPITAL IDEA: The drug developers currently split earnings from Tysabri, but Elan said the new deal will give it capital for investing and growing its business.

DIRECT INJECT: Tysabri is a drug taken intravenously once a month to combat to treat a form of multiple sclerosis that cycles between stages of relapse and remission.


Advertisement


Trending Now



AROUND THE WEB

  1. 1
    Antonin Scalia faults Sonia Sotomayor for 'doubly shameful' suggestion that Michigan voters are...
  2. 2
    The NRA Quietly Backs Down On Domestic Violence
  3. 3
    Tara Lipinski, Johnny Weir to work Kentucky Derby
  4. 4
    Oklahoma basketball: Juco guard set to visit Sooners on Wednesday
  5. 5
    Texas town ready to drink its own toilet water
+ show more